Characteristics and hematological indicators predictors of immunotherapy response in advanced non-small cell lung cancer
Nan Zhao, Xinyu Wu, Wensi Zhao, Xiang Cheng, Hua He, Dedong Cao · 2026
Read Characteristics and hematological indicators predictors of immunotherapy response in advanced non-small cell lung cancer by Nan Zhao, Xinyu Wu, Wensi Zhao, Xiang Cheng, Hua He, Dedong Cao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13471613.txt.
Description
Nan Zhao and colleagues search in 2026 for blood markers that predict which advanced lung cancer patients will benefit from immunotherapy. Checkpoint inhibitor drugs have improved outcomes in non small cell lung cancer, yet gains vary sharply between patients. Their retrospective study gathered 198 patients treated at two Wuhan area hospitals from 2021 to 2023, with a median follow up beyond two years.
Four cheap markers drawn from routine blood work were tested: ratios built from neutrophils, lymphocytes, and platelets, plus an albumin bilirubin score and an enzyme level. The analysis split patients by each marker and compared early response, immune side effects, and survival with and without the drug holding. Statistical models then hunted for independent predictors of progression free and overall survival. The authors hope such markers can guide personalized treatment choices.
Catalog record
| CREATOR | Nan Zhao, Xinyu Wu, Wensi Zhao, Xiang Cheng, Hua He, Dedong Cao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79956 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |